Clinical Trial

A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer

Study acronym: COMICE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2025 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
COMICE is a randomised, double blind placebo controlled Phase II trial. The trial is recruiting 108 patients with advanced recurrent cervical cancer who have completed their 1st line chemotherapy for advanced/recurrent disease. Patients will be randomised to either placebo Cediranib and Olaparib or active Cediranib and Olaparib and will remain on treatment until progression of disease, unacceptable toxicity or withdrawal of consent. Patients will be assessed for disease progression every 8 weeks through CT/MRI imaging. The primary end point is Progression Free Survival.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-07-24.
Status change: Recruiting → Active, Not Recruiting 2025-02-24
Trial Details
NCT Number NCT04487587
Lead Sponsor The Clatterbridge Cancer Centre NHS Foundation Trust
Collaborators: University of Liverpool
Conditions Cervical Cancer
Enrollment 79 participants
Start Date 2018-10-09
Primary Completion 2025-03-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-26